Status:

TERMINATED

Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen

Lead Sponsor:

Judit Pich

Collaborating Sponsors:

Fundacion Clinic per a la Recerca Biomédica

Conditions:

HIV Seropositivity

HIV Infections

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Phase 3b, single arm, simplification study with dual therapy including Lamivudine (300 mg QD) plus Raltegravir (1200 mg QD) in virologically suppressed HIV-1 infected patients experiencing inconvenien...

Eligibility Criteria

Inclusion

  • Eligible patients will be males or females at least 18 years of age. Women of childbearing potential must have a negative pregnancy test within 10 days prior to randomization into the study.
  • Patients seropositive for HIV-1 using standard diagnostic criteria.
  • Patients experiencing inconvenience, toxicity, negative impact on comorbidities or risk of drug-drug interactions with their current regimen
  • Patients virologically suppressed during at least 12 months prior to inclusion (viral load \<50 copies/mL).
  • Patients who have signed informed consent to participate in the study.

Exclusion

  • Pregnancy, lactation, or planned pregnancy during the study period.
  • Previous failure to an integrase inhibitor-containing regimen.
  • Previous failure to a Lamivudine or Emtricitabine-containing regimen.
  • Resistance mutations to Lamivudine or integrase inhibitor if any resistance test had been previously performed.
  • Any disease or history of disease which, in the opinion of the investigator, might confound the results of the study or pose additional risk to patient treatment.
  • Chronic hepatitis B.

Key Trial Info

Start Date :

May 3 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 25 2020

Estimated Enrollment :

17 Patients enrolled

Trial Details

Trial ID

NCT03333083

Start Date

May 3 2018

End Date

June 25 2020

Last Update

May 18 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital Clínic i Provincial de Barcelona

Barcelona, Barcelona, Spain, 08036